Evidence map›Paper›PMID 41535458›Full record

ArticleNature2026

N

Batsheva Rozman, Karin Broennimann, K Shanmugha Rajan, Aharon Nachshon, Chiranjeet Saha, Tamar Arazi, Vishnu Mohan, Tamar Geiger, Clayton J Wollner, Justin M Richner and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Recoding by NNature communications · 2026
    Article
  3. Review
  4. NNature · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Batsheva Rozman *Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. batsheva.frankelrozman@weizmann.ac.il.ORCID 0000-0002-0107-260X
Karin Broennimann *Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
K Shanmugha Rajan *Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-4826-9802
Aharon NachshonDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-2283-5220
Chiranjeet SahaDepartment of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.
Tamar AraziDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Vishnu MohanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-0008-5513
Tamar GeigerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-9526-197X
Clayton J WollnerDepartment of Microbiology and Immunology, College of Medicine, University of Illinois Chicago, Chicago, IL, USA.
Justin M RichnerDepartment of Microbiology and Immunology, College of Medicine, University of Illinois Chicago, Chicago, IL, USA.ORCID 0000-0002-5344-118X
Eric WesthofArchitecture et Réactivité de l'ARN, Université de Strasbourg, Institut de biologie moléculaire et cellulaire du CNRS, Strasbourg, France.
Ada YonathDepartment of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.
Anat BashanDepartment of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-7705-0466
Noam Stern-GinossarDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. noam.stern-ginossar@weizmann.ac.il.ORCID 0000-0003-3583-5932

Funding

Dengue virus mRNA lipid nanoparticle vaccineR01AI150672 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RICHNER, JUSTIN · 2021 to 2024
$2.3M
European Research Council consolidatorNIAID NIH HHS R01 AI150672
6 · The paper itself

Abstract

The considerable success of mRNA vaccines against SARS-CoV-2 has underscored the potential of synthetic mRNA as a transformative biomedical technology

Indexed as

Protein BiosynthesisPseudouridineCodonCryoelectron MicroscopyEukaryotic Initiation Factor-2HumansModels, MolecularPeptide Chain Elongation, TranslationalPeptide Chain Initiation, TranslationalPhosphorylationRibosomesRNA, MessengerCodonEukaryotic Initiation Factor-2PseudouridineRNA, Messenger

Identifiers

PMID41535458

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.